R
ecently the results of the Warfarin Aspirin Recurrent Stroke Study (WARSS) were published. 1 This study investigated whether oral anticoagulation (international normalized ratio [INR] 1.4 to 2.8) is more effective than aspirin in the prevention of ischemic stroke or death after cerebral ischemia of arterial origin. In the early 1990s, at the design phase of the study, the investigators decided to use a low-intensity anticoagulation regimen because they were particularly concerned about the risk of intracranial hemorrhage. At a later stage these concerns were reiterated in correspondence about WARSS. 2 The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) was a trial similar to WARSS except that the intensity of the oral anticoagulation was much higher, with a target range of INR 3.0 to 4.5. 3 SPIRIT was terminated after its first interim analysis because of a statistically and clinically significant excess of major hemorrhages in the anticoagulated patients (relative risk, 9.3; 95% CI, 4.0 to 22) in comparison with the patients who received aspirin. The annual incidence of intracranial hemorrhage was 3.7% in the group on anticoagulants. In 1997 we started a new study, the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), with an intermediate intensity of anticoagulation. At the current stage of the trial we wished to study the incidence of intracranial hemorrhage after cerebral ischemia of arterial origin.
Subjects and Methods
ESPRIT is an open randomized clinical trial comparing (A) oral anticoagulation with a target INR between 2.0 and 3.0 or (B) the See Editorial Comment, page FFF combination of aspirin (30 to 325 mg daily) and dipyridamole (400 mg daily) with (C) aspirin only (same dose). 4, 5 The trial seeks to recruit 4500 patients with a mean follow-up of 3 years. Primary outcome is the composite of vascular death, nonfatal stroke, nonfatal myocardial infarction, or major bleeding complication. All outcome events are recorded at the central trial office, and a committee that has no information about treatment assignment adjudicates classification. An extracranial hemorrhage is defined as major if it results in death or hospital admission. All INR values are collected for patients allocated to anticoagulant treatment. With Rosendaal's method, we calculated the number of patient-years spent in each 0.5-U INR class. 6 above it, and 10.9% below it. The mean achieved INR was 2.6. At the same date, 15 intracranial hemorrhages had been recorded, resulting in an annual incidence of 0.31% (95% CI, 0.18% to 0.52%). In a worst-case scenario, these bleeds would all have occurred in the anticoagulation group, in which a total of 1235 patient-years had been accrued; the worst-case incidence would therefore be 1.21% per year (95% CI, 0.68% to 2.00%). By that time a total of 35 extracranial hemorrhages had been reported, resulting in an overall rate of 0.73% per year or 2.83% with the worst-case scenario. Five patients had 2 bleeding complications.
Results

As of
Discussion
On the basis of the ESPRIT data, the most likely incidence of intracranial hemorrhage is between 0.31% and 1.21% annually in patients after cerebral ischemia of arterial origin anticoagulated with a target INR between 2.0 and 3.0. This incidence compares favorably with that of SPIRIT 3 and is compatible with that of any major hemorrhage in the WARSS trial (3.4% per year); WARSS did not report on intracranial hemorrhage separately. 1 Rates for any major hemorrhage were 7.2% per year in SPIRIT and between 1.1% and 4.1% in ESPRIT. The worst-case scenario probably is an overestimation because the incidence of intracranial hemorrhage after aspirin treatment is in the order of 0.39% (95% CI, 0.22% to 0.80%) per year in similar patients. 3 In a post hoc analysis in SPIRIT, the incidence of major hemorrhages in anticoagulated patients was approximately two thirds lower in those in whom the achieved INR ranged between 2.0 and 3.0 than in those in whom the target range of 3.0 to 4.5 was actually reached. 3 In a direct comparison of data of anticoagulated patients from SPIRIT and the European Atrial Fibrillation Trial (which included patients with cerebral ischemia and atrial fibrillation), we found a 19-fold higher risk of intracranial hemorrhage among the patients with cerebral ischemia of presumed arterial origin if differences between the 2 patient groups were taken into account. 7, 8 In an observational study of INR-specific incidence of ischemic and hemorrhagic events in patients with cerebral ischemia of arterial origin followed by the Leiden anticoagulation clinic, the optimal INR was between 2.5 and 3.5. 9 Thus, we conclude that oral anticoagulation with a target (and achieved) INR of 2.0 to 3.0 is reasonably safe in patients with cerebral ischemia of arterial origin. Of course, conclusions about efficacy cannot be drawn until the end of the ESPRIT study.
